Translational Toxicology and the Work of the Predictive Safety Testing Consortium

被引:25
作者
Mattes, W. B. [1 ]
Walker, E. G. [1 ]
机构
[1] Crit Path Inst, Dept Toxicol, Tucson, AZ USA
关键词
DRUG DEVELOPMENT; INTERDISCIPLINARY RESEARCH; PHARMACEUTICAL-INDUSTRY; BIOMARKERS; TECHNOLOGIES; TOXICITY; BEDSIDE; BENCH;
D O I
10.1038/clpt.2008.270
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Toxicology has always been translational-at least with respect to its primary focus on human "health." The earliest "toxicologists" explored the effects of plant and animal poisons on humans, conducting experiments on (often unsuspecting) human subjects.(1) Not until the sulfanilamide disaster of 1937, the 1938 US Federal Food, Drug and Cosmetic Act, and the Nuremberg Code did animals become central to the experimental assessment of chemical safety.(2,3) Now, with harmonization of requirements among various international regulatory agencies, the types and design of safety evaluation studies conducted to support first-in-human investigations have been reasonably standardized.(4) Most drug safety studies are conducted in both a rodent and a nonrodent species, with the aim of identifying adverse reactions relevant to human health, potential target organs of toxicity, a dose for first-in-human studies, a margin of safety between the efficacious and toxic doses, and strategies for monitoring safety during clinical trials.(5)
引用
收藏
页码:327 / 330
页数:4
相关论文
共 26 条
  • [1] A prototypical process for creating evidentiary standards for biomarkers and diagnostics
    Altar, C. A.
    Amakye, D.
    Bounos, D.
    Bloom, J.
    Clack, G.
    Dean, R.
    Devanarayan, V.
    Fu, D.
    Furlong, S.
    Hinman, L.
    Girman, C.
    Lathia, C.
    Lesko, L.
    Madani, S.
    Mayne, J.
    Meyer, J.
    Raunig, D.
    Sager, P.
    Williams, S. A.
    Wong, P.
    Zerba, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 368 - 371
  • [2] Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective
    Amur, Shashi
    Frueh, Felix W.
    Lesko, Lawrence J.
    Huang, Shiew-Mei
    [J]. BIOMARKERS IN MEDICINE, 2008, 2 (03) : 305 - 311
  • [3] [Anonymous], 1949, NUREMBERG CODE DIREC
  • [4] [Anonymous], 2006, NEPHROL DIAL TRANSPL
  • [5] Safety evaluation to support first-in-man investigations II: Toxicology studies
    Baldrick, Paul
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2008, 51 (02) : 237 - 243
  • [6] An assessment of statin safety by hepatologists
    Cohen, DE
    Anania, FA
    Chalasani, N
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) : 77C - 81C
  • [7] Novel technologies for the discovery and quantitation of biomarkers of toxicity
    Collings, Fitz B.
    Vaidya, Vishal S.
    [J]. TOXICOLOGY, 2008, 245 (03) : 167 - 174
  • [8] Best practices guideline: T6oxicologic histopathology
    Crissman, JW
    Goodman, DG
    Hildebrandt, PK
    Maronpot, RR
    Prater, DA
    Riley, JH
    Seaman, WJ
    Thake, DC
    [J]. TOXICOLOGIC PATHOLOGY, 2004, 32 (01) : 126 - 131
  • [9] New technologies around biomarkers and their interplay with drug development
    Dieterle, Frank
    Marrer, Estelle
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 390 (01) : 141 - 154
  • [10] Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat
    Fielden, Mark R.
    Nie, Alex
    McMillian, Michael
    Elangbam, Chandi S.
    Trela, Bruce A.
    Yang, Yi
    Dunn, Robert T., II
    Dragan, Yvonne
    Fransson-Stehen, Ronny
    Bogdanffy, Matthew
    Adams, Stephen P.
    Foster, William R.
    Chen, Shen-Jue
    Rossi, Phil
    Kasper, Peter
    Jacobson-Kram, David
    Tatsuoka, Kay S.
    Wier, Patrick J.
    Gollu, Jeremy
    Halbert, Donald N.
    Roter, Alan
    Young, Jamie K.
    Sina, Joseph F.
    Marlowe, Jennifer
    Martus, Hans-Joerg
    Aubrecht, Jiri
    Olaharski, Andrew J.
    Roome, Nigel
    Nioi, Paul
    Pardo, Ingrid
    Snyder, Ron
    Perry, Richard
    Lord, Peter
    Mattes, William
    Car, Bruce D.
    [J]. TOXICOLOGICAL SCIENCES, 2008, 103 (01) : 28 - 34